Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal Lactobacillus Capsules for High-Risk HPV Clearance in Postmenopausal Women
ChiCTR2500114563Phase 4Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Dec 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Ding Jun Sheng and interferon alfa-2b in human papillomavirus infection (3 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Clearance rate of high-risk HPV at month 6. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
Ding Jun Shenginterferon alfa-2b
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2500114563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114563.